Lycke M, et al. - In a population of women diagnosed with an unknown ovarian cyst or pelvic tumor, researchers attempted to validate the performance of biomarkers and algorithms for differential diagnosis. They calculated biomarker levels, risk of malignancy algorithm (ROMA), and risk of malignancy index (RMI) for 638 women consecutively enrolled in 6 hospitals in Western Sweden from September 2013 to February 2016. The results were compared with the final pathology report. According to findings, CA125 vs HE4 as a biomarker enabled a better detection of women with ovarian cancer. Benign lesions were more correctly detected with the help of HE4. The identification of these could assist in differential diagnoses to guide the level of care and decrease overtreatment. The findings of this study corroborated prior results from single-center studies and suggested the implementation of HE4 measurement in daily practice.